Protagonist Therapeutics, Inc.
PTGXNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $9.83B
- P/E (TTM)
- 118.56
- Forward P/E
- 70.99
- Dividend yield
- -
- 52-week range
- $73.08$160.81
- Volume (live)
- -
- Avg. volume (3M)
- 799.77K
Protagonist Therapeutics (PTGX) Stock Price & Financial Analysis
Protagonist Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $135.00 - $139.52 |
|---|---|
| 52-Week High | $160.81 |
| 52-Week Low | $73.08 |
| Open | $136.89 |
| Volume (last close) | 409.15K |
| Average Volume (3M) | 799.77K |
| Revenue (TTM) | 281.99M |
|---|---|
| Net Income (TTM) | 82.91M |
| Free Cash Flow (TTM) | 130.22M |
| EPS (TTM) | $1.23 |
| Profit Margin | 29.40% |
| Operating Margin | 20.69% |
| Return on Equity (ROE) | 9.85% |
| Debt to Equity | 0.01 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 9.83B |
|---|---|
| Shares Outstanding | 71.01M |
| P/E Ratio (TTM) | 118.56 |
| Forward P/E | 70.99 |
| Price to Sales (P/S) | 34.86 |
| Price to Book (P/B) | 11.68 |
| EV/EBITDA | 121.13 |
| 50-Day MA | $144.92 |
|---|---|
| 200-Day MA | $114.26 |
| 1-Year Change | +88.59% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Protagonist Therapeutics at a Glance
As of the Oct 23, 2026 close, Protagonist Therapeutics (PTGX) has a market capitalization of $9.83B. The stock trades at 118.6× trailing earnings, 71.0× forward earnings and 34.9× sales. Over the trailing twelve months it earned $82.91M on revenue of $281.99M (a 29.4% profit margin) and generated $130.22M of free cash flow. Revenue grew 34.8% year over year.
As of its latest reported balance sheet, it holds $420.08M in cash and securities against $9.22M of debt, a net cash position of $410.86M.
Protagonist Therapeutics does not currently pay a dividend.
The share price is up 88.6% over the past year. At $138.43 (the Oct 23, 2026 close) it sits within its 52-week range of $73.08 to $160.81, above its 200-day moving average of $114.26.
Based on 14 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $174.58, 26.1% above the Oct 23, 2026 close.
Frequently Asked Questions About Protagonist Therapeutics
What is the current stock price for PTGX?
As of the Oct 23, 2026 close, PTGX stock trades at $138.43. The 52-week range is $73.08–$160.81, with a day range of $135.00–$139.52.
What is the P/E ratio for PTGX?
As of the Oct 23, 2026 close, Protagonist Therapeutics's trailing twelve-month (TTM) P/E ratio is 118.6, meaning investors pay $118.6 for every $1 of annual earnings. The forward P/E is 71.0, reflecting analyst expectations for future earnings. Protagonist Therapeutics operates in the Healthcare sector.
Does PTGX pay dividends?
Protagonist Therapeutics does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for PTGX?
Based on ratings from 14 professional analysts over the last 90 days, the consensus for PTGX is Buy. The average 12-month price target is $174.58, a 26.1% upside from the Oct 23, 2026 close of $138.43.
What is the market cap of PTGX?
As of the Oct 23, 2026 close, Protagonist Therapeutics's market capitalization is $9.83B, classifying it as a mid-cap company. Protagonist Therapeutics operates in the Healthcare sector within the Biotechnology industry.